ArticleCancer cell2018
Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy.
Open access · greenAbstract read
In one paragraph
Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers.
0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
119 citing papers in PubMed, 186 citations in OpenAlex.
- CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts Anti-PD-1 Efficacy in Transgenic Mammary Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Liposomes in tumor treatment: a double-edged sword.Science China. Life sciences · 2026Review
- C5aR1 and cGAS/STING and their possible involvement in radiosensitivity of colorectal cancer.iScience · 2026Review
- Complement system in cancer: friend or foe of immunotherapy.Journal for immunotherapy of cancer · 2026Review
- Macrophages: Targets for next-generation cancer immunotherapy.Cancer cell · 2026Review
- Understanding the role of C5a/C5aR1-mediated complement activation pathway in tumor progression and therapy resistance.Science China. Life sciences · 2026Review
- Article
- The insider's perspective: The intracellular complosome and immune cell dynamics in cancer.Clinical and translational medicine · 2026Review
- The contribution of the membrane-bound complement regulatory proteins CD46 and CD55 in phases of acute lymphocytic leukemia and acute myelogenous leukemia.Scientific reports · 2026Article
- Complement system in tumor growth and metastases.British journal of cancer · 2026Review
- Complement tumor-crosstalk: the role of C5a receptors in urothelial carcinomas.Frontiers in immunology · 2026Review
- Review
- Spatial transcriptomic analysis across histological subtypes reveals molecular heterogeneity and prognostic markers in early-stage lung adenocarcinoma.Clinical and translational medicine · 2025Article
- Neutrophils in cancer: At the crucial crossroads of anti-tumor and pro-tumor.Cancer communications (London, England) · 2025Review
- Enigmatic Roles of Complement Anaphylatoxin Signaling in Health and Disease.Immune network · 2025Review
- Targeting the Kynureninase-HDAC6-Complement Axis as a Novel Therapeutic Strategy in Glioblastoma.Epigenomes · 2025Article
- UPR-induced intracellular C5aR1 promotes adaptation to the hypoxic tumour microenvironment.Cell death & disease · 2025Article
- HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine.Cancer discovery · 2025Article
- C5a/C5aR pathway blocking promoted CuS-mediated cancer therapy effect by inhibiting cuproptosis resistance.Journal for immunotherapy of cancer · 2025Article
59 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors at 2 institutions in 1 country.
Terry R MedlerDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Knight Cancer Research Building Room 3030, 2720 SW Moody Avenue, #KC-CDCB, Portland, OR 97201-5042, USA.
Dhaarini MuruganDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Knight Cancer Research Building Room 3030, 2720 SW Moody Avenue, #KC-CDCB, Portland, OR 97201-5042, USA.
Wesley HortonDepartment of Biomedical Engineering, Program in Computational Biology, Oregon Health & Science University, Portland, OR 97239, USA.
Sushil KumarDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Knight Cancer Research Building Room 3030, 2720 SW Moody Avenue, #KC-CDCB, Portland, OR 97201-5042, USA.
Tiziana CotechiniDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Knight Cancer Research Building Room 3030, 2720 SW Moody Avenue, #KC-CDCB, Portland, OR 97201-5042, USA.
Alexandra M ForsythDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Knight Cancer Research Building Room 3030, 2720 SW Moody Avenue, #KC-CDCB, Portland, OR 97201-5042, USA.
Patrick LeyshockDepartment of Biomedical Engineering, Program in Computational Biology, Oregon Health & Science University, Portland, OR 97239, USA.
Justin J LeitenbergerDepartment of Dermatology, Oregon Health & Science University, Portland, OR 97239, USA.
Molly Kulesz-MartinDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Knight Cancer Research Building Room 3030, 2720 SW Moody Avenue, #KC-CDCB, Portland, OR 97201-5042, USA; Department of Dermatology, Oregon Health & Science University, Portland, OR 97239, USA; Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.
Adam A MargolinDepartment of Biomedical Engineering, Program in Computational Biology, Oregon Health & Science University, Portland, OR 97239, USA; Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.
Zena WerbDepartment of Anatomy, Helen Diller Family Comprehensive Cancer Center, Parker Immunotherapy Cancer Institute, University of California, San Francisco, CA 94143, USA.
Lisa M CoussensDepartment of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Knight Cancer Research Building Room 3030, 2720 SW Moody Avenue, #KC-CDCB, Portland, OR 97201-5042, USA; Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA. Electronic address: coussenl@ohsu.edu.
Oregon Health & Science University · USUCSF Helen Diller Family Comprehensive Cancer Center · US
Funding
Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Grace B Gill · 1997 to 2026
$60.5MRole of Metalloproteinases in Mammary Gland RemodelingR01CA057621 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WERB, ZENA · 1993 to 2017
$9.0MTraining in the Molecular Basis of Skin/Mucosa PathobiologyT32CA106195 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI KULESZ-MARTIN, MOLLY F. · 2004 to 2018
$3.8MIlluminating molecular targetable pathways in HNSCCR01CA192405 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI MCWEENEY, SHANNON K. · 2015 to 2019
$2.5MLeukocyte Biomarkers for Predicting Human Breast Cancer OutcomesU54CA163123 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COUSSENS, LISA M., DALDRUP-LINK, HEIKE ELIZABETH · 2011 to 2015
$2.0MRegulation of Inflammation-Associated Epithelial Cancer DevelopmentR01CA130980 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COUSSENS, LISA M. · 2008 to 2012
$1.6MRegulating the Immune Microenvironment in Breast CancerR01CA155331 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COUSSENS, LISA M. · 2011 to 2015
$1.6MNCI NIH HHS P30 CA069533NCI NIH HHS R01 CA057621NCI NIH HHS R01 CA130980NCI NIH HHS R01 CA155331NCI NIH HHS R01 CA192405NCI NIH HHS T32 CA106195NCI NIH HHS U54 CA163123
Abstract
Complement is a critical component of humoral immunity implicated in cancer development; however, its biological contributions to tumorigenesis remain poorly understood. Using the K14-HPV16 transgenic mouse model of squamous carcinogenesis, we report that urokinase (uPA)
Indexed as
Drug TherapyAnimalsCarcinogenesisCarcinoma, Squamous CellCD8-Positive T-LymphocytesComplement C5aDisease Models, AnimalHumansMacrophagesMiceReceptor, Anaphylatoxin C5aSignal TransductionC5ar1 protein, mouseComplement C5aReceptor, Anaphylatoxin C5aCD8(+) T cellcomplement C5aimmunotherapyinflammationmacrophagesquamous cell carcinomaurokinase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.